Citations

Clear

511 citation(s) found for "Seth, N".

The Role of Variation at AβPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease
Gerrish, Amy , Russo, Giancarlo , Richards, Alexander , Moskvina, Valentina, Ivanov, Dobril , Harold, Denise , Sims, Rebecca , Abraham, Richard, Hollingworth, Paul, Chapman, Jade , Hamshere, Marian L. , Pahwa, Jaspreet Singh, Dowzell, Kimberley, Jones, Nicola, Thomas, Charlene , Stretton, Alexandra, Morgan, Angharad R., Lovestone, Simon , Powell, John , Proitsi, Petroula , Brayne, Carol , Gill, Michael , Lynch, Aoibhinn, Morgan, Kevin , Brown, Kristelle, Passmore, Peter , Craig, David W. , McGuinness, Bernadette , Todd, Stephen , Johnston, Janet, Smith, A. David , Love, Seth , Kehoe, Patrick G. , Hardy, John , Mead, Simon , Fox, Nick C. , Rossor, Martin N. , Collinge, John, Maier, Wolfgang, Jessen, Frank , Kölsch, Heike, Schürmann, Britta, Bussche, Hendrik van den, Heuser, Isabella , Kornhuber, Johannes , Wiltfang, Jens , Dichgans, Martin , Frölich, Lutz, Hampel, Harald , Hüll, Michael, Goate, Alison , Kauwe, John, Cruchaga, Carlos , Nowotny, Petra, Morris, John C. , Mayo, Kevin H. , Livingston, Gill , Gurling, Hugh, McQuillin, Andrew , Gwilliam, Rhian, Deloukas, Panagiotis, Davies, Gail , Starr, John M. , Deary, Ian J. , Al‐Chalabi, Ammar , Shaw, Christopher E. , Tsolaki, Magda , Singleton, Andrew B., Guerreiro, Rita , Mühleisen, Thomas W. , Nöthen, Markus M. , Moebus, Susanne , Jöckel, Karl‐Heinz , Klopp, Norman, Wichmann, H‐Erich, Carrasquillo, Minerva M., Younkin, Steven G., Jones, Lesley , Holmans, Peter , O‘Donovan, Michael , Williams, Julie , Deloukas, Panos , Escott‐Price, Valentina , Denning, Nicola , Dichgans, Martin , Cruchaga, Carlos , Kornhuber, Johannes , Nöthen, Markus M , Hardy, John , Moebus, Susanne , Williams, Amy L. , Lupton, Michelle K. , Rubinsztein, David Chaim , LAWLOR, BRIAN A. , Holmes, Clive , Mann, David , Heun, Reinhard , Rujescu, Dan , Bass, Nicholas , Harris, Sarah , Carrasquillo, Minerva M. , Pankratz, V. Shane , Owen, Michael J. , Fox, Nick C , Morris, John C , Wiltfang, Jens , Al-Chalabi, Ammar , Tsolaki, Magda , Goate, Alison M , McQuillin, Andrew , Escott-Price, Valentina

Mayo Clinic

Journal of Alzheimer's Disease | May 16, 2018 | Volume: 28 | Issue: 2 | Pages: 377-387

10.3233/jad-2011-110824 | PMID 22027014 Get It

Insulin increases ventilation during euglycemia in humans
Barbosa, Thales C. , Kaur, Jasdeep , Holwerda, Seth W. , Young, Colin N. , Curry, Timothy B. , Thyfault, John P. , Limberg, Jacqueline K. , Joyner, Michael J. , Fadel, Paul J.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | March 28, 2018 | Volume: 315 | Issue: 1 | Pages: R84-R89

10.1152/ajpregu.00039.2018 | PMID 29590558 Get It

Evidence from animal studies indicates that hyperinsulinemia, without changes in glucose, increases ventilation via a carotid body-mediated mechanism. However, whether insulin elevates ventilation in humans independently of changes in glucose remains unclear. Therefore, we tested the hypothesis that insulin increases ventilation in humans during a hyperinsulinemic-euglycemic clamp in which insulin was elevated to postprandial concentrations while glucose was maintained at fasting concentrations. First, in 16 healthy young men ( protocol 1), we retrospectively analyzed respiration rate and estimated tidal volume from a pneumobelt to calculate minute ventilation during a hyperinsulinemic-euglycemic clamp. In addition, for a direct assessment of minute ventilation during a hyperinsulinemic-euglycemic clamp, we retrospectively analyzed breath-by-breath respiration rate and tidal volume from inspired/expired gasses in an additional 23 healthy young subjects ( protocol 2). Clamp infusion elevated minute ventilation from baseline in both protocols ( protocol 1: +11.9 ± 4.6% baseline, P = 0.001; protocol 2: +9.5 ± 3.8% baseline, P = 0.020). In protocol 1, peak changes in both respiration rate (+13.9 ± 3.0% baseline, P < 0.001) and estimated tidal volume (+16.9 ± 4.1% baseline, P = 0.001) were higher than baseline during the clamp. In protocol 2, tidal volume primarily increased during the clamp (+9.7 ± 3.7% baseline, P = 0.016), as respiration rate did not change significantly (+0.2 ± 1.8% baseline, P = 0.889). Collectively, we demonstrate for the first time in humans that elevated plasma insulin increases minute ventilation independent of changes in glucose.
Gastrointestinal: Superinfection of a large cystic mucinous pancreatic neoplasm
Sunjaya, Dharma , Jacobi, J., Sweetser, Seth , Sunjaya, D

Mayo Clinic

Journal of Gastroenterology and Hepatology | March 15, 2018 | Volume: 33 | Issue: 4 | Pages: 770-770

10.1111/jgh.13993 | PMID 29542244 Get It

Accuracy of detecting enlargement of aneurysms using different MRI modalities and measurement protocols
Nakagawa, Daichi , Nagahama, Yasunori , Policeni, Bruno , Raghavan, Madhavan L. , Dillard, Seth, Schumacher, Anna , Sarathy, Srivats, Wilson, Saul, Allan, Lauren , Woo, Henry H. , Cloft, Harry J. , Torner, James C., Brown, Robert D., Torner, James C. , Dlouhy, Brian J , Huston, John , Wintermark, Max , Hasan, David

Mayo Clinic

Journal of Neurosurgery | March 9, 2018 | Volume: 130 | Issue: 2 | Pages: 559-565

10.3171/2017.9.jns171811 | PMID 29521585 Get It

OBJECTIVEAneurysm growth is considered predictive of future rupture of intracranial aneurysms. However, how accurately neuroradiologists can reliably detect incremental aneurysm growth using clinical MRI is still unknown. The purpose of this study was to assess the agreement rate of detecting aneurysm enlargement employing generally used MRI modalities.METHODSThree silicone flow phantom models, each with 8 aneurysms of various sizes at different sites, were used in this study. The aneurysm models were identical except for an incremental increase in the sizes of the 8 aneurysms, which ranged from 0.4 mm to 2 mm. The phantoms were imaged on 1.5-T and 3-T MRI units with both time-of-flight (TOF) and contrast-enhanced MR angiography. Three independent expert neuroradiologists measured the aneurysms in a blinded manner using different measurement approaches. The individual and agreement detection rates of aneurysm enlargement among the 3 experts were calculated.RESULTSThe mean detection rate of any increase in any aneurysmal dimension was 95.7%. The detection rates of the 3 observers (observers A, B, and C) were 98.0%, 96.6%, and 92.7%, respectively (p = 0.22). The detection rates of each MRI modality were 91.3% using 1.5-T TOF, 97.2% using 1.5-T with Gd, 95.8% using 3.0-T TOF, and 97.2% using 3.0-T with Gd (p = 0.31). On the other hand, the mean detection rate for aneurysm enlargement was 54.8%. Specifically, the detection rates of observers A, B, and C were 49.0%, 46.1%, and 66.7%, respectively (p = 0.009). As the incremental enlargement value increased, the detection rate for aneurysm enlargement increased. The use of 1.5-T Gd improved the detection rate for small incremental enlargement (e.g., 0.4–1 mm) of the aneurysm (p = 0.04). The location of the aneurysm also affected the detection rate for aneurysm enlargement (p < 0.0001).CONCLUSIONSThe detection rate and interobserver agreement were very high for aneurysm enlargement of 0.4–2 mm. The detection rate for at least 1 increase in any aneurysm dimension did not depend on the choice of MRI modality or measurement protocol. Use of Gd improved the accuracy of measurement. Aneurysm location may influence the accuracy of detecting enlargement.
S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.
Catherine, Tangen, Lucia, M. Scott , Bivalacqua, Trinity J. , Kassouf, Wassim , Bangs, Richard Carlton, Plets, Melissa , Black, Peter C. , Lerner, Seth P. , McConkey, David James , Woods, Michael E. , Thompson, Ian M. , Singh, Parminder Pal

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS527-TPS527

10.1200/jco.2018.36.6_suppl.tps527 Get It

TPS527 Background: Radical cystectomy is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC). Based on the reported efficacy of atezolizumab in metastatic urothelial carcinoma and the known expression of PD-L1 expression in NMIBC after BCG therapy, this trial will evaluate the activity of atezolizumab in BCG-unresponsive high risk NMIBC. Methods: This is a single arm phase II trial testing systemic atezolizumab (1200 mg IV) every 3 weeks for one year in 135 patients with BCG-unresponsive high risk NMIBC. The study will enroll 70 patients with CIS (with or without concomitant Ta/T1) and 65 with Ta/T1 only. Patients with CIS at baseline will undergo mandatory repeat biopsy at 6 months, and all other patients only for suspected recurrence. Patients with persistent CIS, high grade Ta/T1 recurrence or progression to muscle invasive or metastatic disease will be taken off treatment. The co-primary endpoints are: (1) complete response (CR) at 6 months in the CIS subgroup, and (2) event-free survival (EFS) at 18 months in the overall population. A hierarchical approach will be used to test the two co-primary endpoints. Secondary endpoints include duration of CR as well as progression-free, cystectomy-free, bladder cancer-specific, and overall survival in all patients. Response will be correlated to expression of PD-L1 and CD8 by IHC, and to molecular subtypes and immune signatures by RNA-sequencing. If ≥28 (40%) CIS patients respond, the agent will be considered promising. This design has a significance level of 4.6%, and a power of 96%. If the lower bound of the 90% confidence interval of the 18-month EFS excludes 20%, the investigators will conclude the regimen significantly improves EFS relative to historical data (type I error rate 0.05 and statistical power 0.93). Successful completion of this trial could lead to a new treatment paradigm for patients with BCG-unresponsive high risk NMIBC. Funding: NIH/NCI grants: CA180888, CA180819, CA180820, CA180821, and CA180863. Clinical trial registry: NCT02844816 Clinical trial information: NCT02844816.
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues
Khan, Aadil , Paget, James , McLaughlin, Martin , Kyula, Joan , Wilkinson, Michelle, Pencavel, Timothy, Roulstone, Victoria , Seth, Rohit , Halle, Martin , Somaiah, Navita , Boult, Jessica K.R. , Robinson, Simon P. , Pandha, Hardev , Vile, Richard G. , Melcher, Alan , Harrington, Kevin J. , Khan, Aadil A , Paget, James T , Kyula, Joan N , Roulstone, Victoria , Halle, Martin , Boult, Jessica K R , Robinson, Simon P , Melcher, Alan A , Harrington, Kevin , McLaughlin, Martin , Pencavel, Tim D., Mansfield, David , Harris, Paul A.

Mayo Clinic

Science Translational Medicine | January 24, 2018 | Volume: 10 | Issue: 425 | Pages: No page available

10.1126/scitranslmed.aar2041 | PMID 29367346 Get It

Vascular protection using gene therapy can reduce the late toxicities of radiotherapy.
Utility of the multitarget stool DNA test for detection of colorectal neoplasia
Sweetser, Seth , Ahlquist, David A.

Mayo Clinic

Colorectal Cancer | December 21, 2017 | Volume: 6 | Issue: 3 | Pages: 83-94

10.2217/crc-2017-0010 Get It

Tokyo Guidelines 2018: surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos)
Wakabayashi, Go , Iwashita, Yukio , Hibi, Taizo , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Endo, Itaru , Umezawa, Akiko , Asai, Koji , Mori, Yasuhisa , Okamoto, Kohji , Pitt, Henry A. , Hwang, Tsann‐Long , Choi, In‐Seok , Huang, Wayne Shih‐Wei, Giménez, Mariano , Garden, O. James , Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Jagannath, P., Chan, Angus C. W., Lau, Wan Yee , Liu, Keng‐Hao, Su, Cheng‐Hsi, Misawa, Takeyuki , Tagaya, Nobumi, Fujioka, Shuichi , Higuchi, Ryota , Shikata, Satoru , Noguchi, Yoshinori , Yokoe, Masamichi, Cherqui, Daniel , Sugioka, Atsushi , Santibáñes, Eduardo de , Supe, Avinash , Tokumura, Hiromi, Kimura, Taizo, Yoshida, Masahiro , Mayumi, Toshihiko , Kitano, Seigo, Inomata, Masafumi , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Yoon, Yoo-Seok , Yoon, Dong Sup , Nakamura, Masafumi , Horiguchi, Akihiko , Ukai, Tomohiko , Honda, Goro , Hirata, Koichi

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | November 2, 2017 | Volume: 25 | Issue: 1 | Pages: 73-86

10.1002/jhbp.517 | PMID 29095575 Get It

Abstract In some cases, laparoscopic cholecystectomy (LC) may be difficult to perform in patients with acute cholecystitis (AC) with severe inflammation and fibrosis. The Tokyo Guidelines 2018 (TG18) expand the indications for LC under difficult conditions for each level of severity of AC. As a result of expanding the indications for LC to treat AC, it is absolutely necessary to avoid any increase in bile duct injury (BDI), particularly vasculo‐biliary injury (VBI), which is known to occur at a certain rate in LC. Since the Tokyo Guidelines 2013 (TG13), an attempt has been made to assess intraoperative findings as objective indicators of surgical difficulty; based on expert consensus on these difficulty indicators, bail‐out procedures (including conversion to open cholecystectomy) have been indicated for cases in which LC for AC is difficult to perform. A bail‐out procedure should be chosen if, when the Calot's triangle is appropriately retracted and used as a landmark, a critical view of safety (CVS) cannot be achieved because of the presence of nondissectable scarring or severe fibrosis. We propose standardized safe steps for LC to treat AC. To achieve a CVS, it is vital to dissect at a location above (on the ventral side of) the imaginary line connecting the base of the left medial section (Segment 4) and the roof of Rouvière's sulcus and to fulfill the three criteria of CVS before dividing any structures. Achieving a CVS prevents the misidentification of the cystic duct and the common bile duct, which are most commonly confused. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.
Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis
Mayumi, Toshihiko , Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Solomkin, Joseph S. , Schlossberg, David, Pitt, Henry A. , Yoshida, Masahiro , Gomi, Harumi , Miura, Fumihiko, Garden, O. James , Kiriyama, Seiki , Yokoe, Masamichi, Endo, Itaru , Asbun, Horacio J. , Iwashita, Yukio , Hibi, Taizo , Umezawa, Akiko , Itoi, Takao , Hata, Jiro , Hwang, Tsann‐Long , Dervenis, Christos, Asai, Koji , Mori, Yasuhisa , Huang, Wayne Shih‐Wei, Belli, Giulio, Jagannath, P., Cherqui, Daniel , Kozaka, Kazuto , Baron, Todd H. , Santibáñes, Eduardo de , Higuchi, Ryota , Wada, Keita, Gouma, Dirk J., Deziel, Daniel J., Liau, Kui‐Hin, Wakabayashi, Go , Padbury, Robert , Jonas, Eduard , Supe, Avinash , Singh, Harjit , Gabata, Toshifumi , Chan, Angus C. W., Lau, Wan Yee , Fan, Sheung Tat , Chen, Miin‐Fu , Ker, Chen‐Guo , Choi, In‐Seok , Kim, Myung‐Hwan , Kitano, Seigo, Inomata, Masafumi , Inui, Kazuo, Sumiyama, Yoshinobu, Yamamoto, Masakazu , Suzuki, Kenji S. , Han, Ho-Seong , Mukai, Shuntaro , Yoon, Yoo-Seok , Yoon, Dong Sup , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | November 1, 2017 | Volume: 25 | Issue: 1 | Pages: 96-100

10.1002/jhbp.519 | PMID 29090868 Get It

Abstract Management bundles that define items or procedures strongly recommended in clinical practice have been used in many guidelines in recent years. Application of these bundles facilitates the adaptation of guidelines and helps improve the prognosis of target diseases. In Tokyo Guidelines 2013 ( TG 13), we proposed management bundles for acute cholangitis and cholecystitis. Here, in Tokyo Guidelines 2018 ( TG 18), we redefine the management bundles for acute cholangitis and cholecystitis. Critical parts of the bundles in TG 18 include the diagnostic process, severity assessment, transfer of patients if necessary, and therapeutic approach at each time point. Observance of these items and procedures should improve the prognosis of acute cholangitis and cholecystitis. Studies are now needed to evaluate the dissemination of these TG 18 bundles and their effectiveness. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.